News and Events
In the News
Small PBMs Urge Congress: Don't Kill Rebates
Smaller pharmacy benefit management companies, rarely in the spotlight, are urging Congress not to fundamentally alter the way prescription drugs are paid for in the U.S. As the Trump administration advocates banning rebates under Medicare and Medicaid, these lower-profile PBMs aim to convince lawmakers not to junk the entire system. They say Congress should start by examining business models other than just of the nation's largest PBM players.
Policy Makers Seek Answers for High Costs of Prescription Drugs
- Pharmacy Times
Members of Congress sought to deconstruct the drug supply chain Thursday in an effort to find ways to lower prescription drug prices. Hosted by the House Committee on Energy & Commerce, the investigational hearing drew testimony from health care industry experts representing drug companies, insurers, and patient advocacy groups.
PBM executive: Industry has been discussing end of rebates for a 'long, long time'
Though the Trump administration’s steps to end drug rebates have been met with outrage from pharmacy benefit managers (PBMs), these companies have been talking about a future without rebates for a long time, experts say.
We pass 100% of all discounts or rebates we receive directly back to you. All of our revenue is based on a set admin fee.Learn more